IDEXX Laboratories, Inc. vs Rockwell Automation — how do they compare? IDEXX Laboratories, Inc. trades at $519.93 (market cap $40.43B), while Rockwell Automation trades at $432.3 (market cap $48.21B). The key difference: Rockwell Automation is the larger of the two by market cap, and Rockwell Automation pays a 1.27% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Rockwell Automation for 74 Days on average.
| IDXX | ROK | |
|---|---|---|
Market Cap | $40.43B | $48.21B |
Volume | 692,164 | 953,342 |
Sector | Health | Industrials |
52-Week High | $766.68 | $495.08 |
52-Week Low | $504.70 | $333.75 |
Typical Hold Time | 46 Days | 74 Days |
Enterprise Value | $41.32B | $51.34B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Rockwell Automation (ROK) trades at $439.01, down 0.65% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company maintains solid profitability with a 13.38% net income margin and 34.47% ROE, though valuation ratios like a P/E of 40.65 appear elevated. Recent news highlights leadership in industrial automation, including partnerships in AI cybersecurity and new robotic platforms, supporting positive sector momentum.
The outlook is cautiously optimistic, with a consensus price target of $489.89 implying ~12% upside, but high valuation and macroeconomic pressures pose risks. Earnings growth and automation demand are key catalysts, yet investors face volatility from competitive and economic headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →